Publication | Open Access

Target: a Randomized, Phase Ii Trial Comparing Vintafolide Versus Vintafolide Plus Docetaxel, Versus Docetaxel Alone in Second-Line Treatment of Folate-Receptor-Positive Non-Small Cell Lung Cancer (Nsclc) Patients

Second-line TreatmentOncologyMedicinePharmacotherapyVersus Docetaxel AloneAnti-cancer AgentCancer TreatmentPharmacologyRadiation OncologyLung Cancer